Physician profile
Goddard Lainjo
NPI 1326048224
$16,363.11
in general payments reported to CMS, 2019-2025
30 companies · $3,498 in 2025
The $3,498 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $777 · 2021: $1,774 · 2022: $2,109 · 2023: $3,452 · 2024: $3,966 · 2025: $3,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,490.22 |
| Education | $425.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,664.89 | 2019-2025 | |
| Janssen Biotech, INC. | $2,371.49 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $1,651.96 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $1,398.38 | 2020-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals Lp | $1,377.64 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $1,156.42 | 2020-2025 | Acthar |
| Pfizer INC. | $1,076.90 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $836.52 | 2021-2025 | |
| Lilly USA, LLC | $784.26 | 2019-2024 | Taltz, Olumiant |
| Glaxosmithkline, LLC. | $654.24 | 2019-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $470.64 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $232.93 | 2019-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $221.80 | 2023-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $213.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.59 | 2020-2025 | Cyltezo, Ofev |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $152.37 | 2021-2022 | |
| Genzyme Corporation | $147.28 | 2020-2025 | |
| Axsome Therapeutics, INC. | $147.16 | 2024-2025 | Auvelity |
| Actelion Pharmaceuticals US, INC. | $118.13 | 2023-2024 | Uptravi, Opsumit |
| Fresenius Kabi USA, LLC | $103.86 | 2023 | Idacio |
| Organon LLC | $70.51 | 2023-2024 | Hadlima, Renflexis |
| Sandoz INC. | $53.56 | 2024-2025 | Hyrimoz |
| Sobi, INC | $46.65 | 2023 | |
| Genentech USA, INC. | $33.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $32.24 | 2024 | Orencia |
| Celltrion USA INC. | $31.56 | 2023 | Yuflyma |
| Antares Pharma, INC. | $30.33 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $26.87 | 2024 | Arcalyst |
| Medexus Pharma, INC. | $26.32 | 2019 | |
| Celgene Corporation | $18.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Goddard Lainjo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.